Kristyl Woolsey, APRN
Nurse Practitioner · Hot Springs, ARNPI 1871976852
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 269 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$940
- Amgen$394
- Insulet Corporation$363
- Lilly USA, LLC$280
- Radius Health, Inc.$277
- Bayer$241
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,286100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 97 | $940 |
| Amgen | 31 | $394 |
| Insulet Corporation | 8 | $363 |
| Lilly USA, LLC | 14 | $280 |
| Radius Health, Inc. | 10 | $277 |
| Bayer | 14 | $241 |
| Sanofi-aventis U.S. LLC | 15 | $236 |
| Boehringer Ingelheim | 12 | $228 |
| Abbott | 9 | $189 |
| Tandem Diabetes Care, Inc. | 8 | $182 |
| Novartis | 7 | $151 |
| AstraZeneca(2 entities) | 8 | $132 |
| AbbVie | 6 | $122 |
| Novo Nordisk | 7 | $120 |
| Medtronic | 6 | $96 |
| BETA Bionics, Inc. | 3 | $79 |
| Ascendis Pharma Endocrinology Inc | 3 | $68 |
| Antares Pharma, Inc. | 3 | $53 |
| Corcept Therapeutics | 3 | $47 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Sequel Med Tech, LLC | 1 | $19 |
| Merck | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$123
How this compares
$4,286 in reported general payments places this provider in the 90th percentile of 697 nurse practitioner providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 357 | $501,905 |
| MounjaroTirzepatide | 293 | $353,780 |
| Tresiba Flextouch U-100Insulin Degludec | 345 | $264,007 |
| ProliaDenosumab | 149 | $259,694 |
| JanuviaSitagliptin Phosphate | 183 | $158,874 |
| FarxigaDapagliflozin Propanediol | 204 | $145,942 |
| JardianceEmpagliflozin | 124 | $130,882 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $89,084 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 99 | $83,972 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $77,257 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 418 | $73,627 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 109 | $67,741 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 226 | $61,107 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 24 | $59,913 |
| TymlosAbaloparatide | 19 | $58,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $120 | $506,132378 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $280 | $411,027417 claims |
| AmgenProlia, Evenity (2 Syringes) | $394 | $319,607173 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $228 | $176,019199 claims |
| MerckJanuvia | $17 | $158,874183 claims |
| AstraZenecaFarxiga | $132 | $145,942204 claims |
| Radius Health, Inc.Tymlos | $277 | $58,98319 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $236 | $22,10136 claims |
| AbbVieSynthroid | $122 | $4,41052 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 697 nurse practitioner providers in Arkansas.
Other nurse practitioner in Hot Springs
- Tiffany McConathyHot Springs$54K
- Virginia LaliberteHot Springs$21K
- Samantha WidemanHot Springs$14K
- Cody WilliamsHot Springs$12K
- Nan MeansHot Springs$7K
- Ragan ArrisonHot Springs$7K
- Laci PattonHot Springs$7K
- Samantha BollanHot Springs$7K
- Kayla HarringtonHot Springs$6K
- Mindy FarmerHot Springs$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.